Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
| PHPIX Fund | USD 27.85 0.48 1.75% |
Slightly above 54% of Pharmaceuticals Ultrasector's investors are presently thinking to get in. The analysis of overall sentiment of trading Pharmaceuticals Ultrasector Profund mutual fund suggests that some investors are interested at this time. Pharmaceuticals Ultrasector's investing sentiment can be driven by a variety of factors including economic data, Pharmaceuticals Ultrasector's earnings reports, geopolitical events, and overall market trends.
Pharmaceuticals |
Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunol
Read at businesswire.com
 |
Pharmaceuticals Ultrasector Fundamental Analysis
We analyze Pharmaceuticals Ultrasector's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmaceuticals Ultrasector using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmaceuticals Ultrasector based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Pharmaceuticals Ultrasector is currently under evaluation in price to book among similar funds. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Pharmaceuticals Ultrasector Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharmaceuticals Ultrasector mutual fund to make a market-neutral strategy. Peer analysis of Pharmaceuticals Ultrasector could also be used in its relative valuation, which is a method of valuing Pharmaceuticals Ultrasector by comparing valuation metrics with similar companies.
Peers
Pharmaceuticals Ultrasector Related Equities
| LGPSX | Profunds Large | 0.87 | ||||
| LGPIX | Large Cap | 0.85 | ||||
| UIPSX | Ultrashort Mid-cap | 0.71 | ||||
| UIPIX | Ultrashort Mid-cap | 0.69 | ||||
| BRPIX | Bear Profund | 0.44 | ||||
| BRPSX | Bear Profund | 0.39 | ||||
| SRPSX | Short Real | 0.61 | ||||
| SRPIX | Short Real | 0.65 | ||||
| TEPIX | Technology Ultrasector | 2.08 | ||||
| TEPSX | Technology Ultrasector | 2.08 |
Other Information on Investing in Pharmaceuticals Mutual Fund
Pharmaceuticals Ultrasector financial ratios help investors to determine whether Pharmaceuticals Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaceuticals with respect to the benefits of owning Pharmaceuticals Ultrasector security.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |